# Code Biotherapeutics

> Code Biotherapeutics is a privately held Philadelphia-area biotechnology company developing 3DNA, a synthetic, multivalent DNA scaffold intended to carry genetic medicines to selected cells without using a viral vector. Its lead internal work is in Duchenne muscular dystrophy, with additional targeting research in organs including the lung, pancreas and liver, while a Takeda collaboration applies the platform to rare-disease programs. The pitch is modularity: attach a targeting molecule and a therapeutic cargo to an off-the-shelf scaffold, then tune the resulting medicine. The proof disclosed publicly remains preclinical, making translation into humans the central test.

- **Founded:** 2020
- **Headquarters:** Hatfield, Pennsylvania, United States
- **Founders:** Brian P. McVeigh (Chairman, Chief Executive Officer and Co-Founder), Robert C. Getts, Ph.D. (Chief Platform Technologies Officer and Co-Founder)
- **Team size:** 23 employees listed on LinkedIn; company size band 11-50
- **Products:** 3DNA platform, Duchenne muscular dystrophy discovery program, Organ-targeted discovery programs, Partnered genetic-medicine development
- **Notable:** Raised $85 million across a $10 million seed financing and a $75 million Series A., Signed a Takeda collaboration with double-digit millions in upfront, near-term milestone and research funding and up to $2 billion in conditional program milestones., Built an internal Duchenne muscular dystrophy discovery program around delivery of large genetic payloads.

## Products & services

- **3DNA platform** — A proprietary multivalent synthetic DNA scaffold designed to carry nucleic-acid therapeutics and targeting molecules for cell- and tissue-specific, non-viral delivery.
- **Duchenne muscular dystrophy discovery program** — The company's most advanced disclosed internal research program, intended to address limits of AAV-based delivery, including truncated payloads, toxicity and inability to re-dose.
- **Organ-targeted discovery programs** — Preclinical targeting work disclosed for tissues including lung, pancreas and liver, with additional discovery described for ear, heart and kidney.
- **Partnered genetic-medicine development** — Research collaborations in which Code Bio applies 3DNA to partner-selected programs; the disclosed Takeda agreement covers a liver-directed rare disease program and studies for CNS programs.

## Achievements

- Raised $85 million across a $10 million seed financing and a $75 million Series A.
- Signed a Takeda collaboration with double-digit millions in upfront, near-term milestone and research funding and up to $2 billion in conditional program milestones.
- Built an internal Duchenne muscular dystrophy discovery program around delivery of large genetic payloads.
- Published or contributed to preclinical studies of 3DNA targeting in lung and pancreatic tumor models.
- Reported a 424-fold lung-targeting specificity index for one anti-ICAM 3DNA formulation versus a matching IgG formulation in a mouse study.
- Presented as a privately funded gene and cell therapy company at the 2023 BIO International Convention.

## Latest updates

- **2023-06** — Code Bio presented its platform and discovery-stage DMD program at the BIO International Convention.
- **2023-06** — A peer-reviewed Translational Oncology paper reported preclinical delivery of imaging and siRNA payloads to pancreatic tumor models using targeted 3DNA formulations.
- **2023-05** — A U.S. patent application covering nucleic-acid carriers and therapeutic methods of use was published and assigned to Code Biotherapeutics.
- **2022-11** — Alex S. Tracy, Ph.D., joined as Chief Technical Officer to lead process, analytical and manufacturing strategy.
- **2022-09** — David Anderson, Ph.D., was appointed Chief Scientific Officer.

## Links

- Website: https://www.codebiotx.com/
- LinkedIn: https://www.linkedin.com/company/code-biotherapeutics/
- Twitter/X: https://www.twitter.com/CodeBioTx/

---

Profile page: https://yespress.io/code-biotherapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-08-21